Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Kalaris Therapeutics IncNASDAQ: KLRS
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses grows, but more slowly than its trailing trend
Q1 FY2026 other income / expenses of $977K rose 518.4% year over year, behind the +1344.0% change in trailing-twelve-month other income / expenses. Sequentially, it rose 21.7% from the prior quarter.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +518.4% toward the trailing-twelve-month pace of +1344.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 2.71M USD
- Year-over-year change
- +177.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.71M | +177.3% |
| FY2024 | 2024-12-31 | (3.51M) | -184.5% |
| FY2023 | 2023-12-31 | (1.24M) | +16.5% |
| FY2022 | 2022-12-31 | (1.48M) | -30.1% |
| FY2021 | 2021-12-31 | (1.14M) | — |
Other Income / Expenses vs competitors
How KLRS compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1344.0% is the highest of 9, against a peer median of -42.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.57M USD | -26.4% | +162.8% | 330.9% | |
IMAImageneBio Inc | LTM Mar 2026 | $10.53M USD | +5.4% | +8.8% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $5M USD | -50.6% | +65.3% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $3.53M USD | +1344.0% | — | — |
| LTM Mar 2026 | $3.29M USD | -17.6% | +87.2% | — | |
| FY2025 | $2.79M USD | -60.4% | +22.4% | 4360.9% | |
| LTM Mar 2026 | $2.79M USD | -35.2% | +24.9% | 279.0% | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -$38.64M USD | -613.7% | — | 38.8% | |
| Peer median (excluding KLRS) | — | -42.9% | +24.9% | 330.9% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.12M | 0 | 0 | 0 | 13K |
| Gross Profit | (1.12M) | 0 | 0 | 0 | (13K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 119.62M | 11.76M | 11.71M | 12.34M | 30.75M |
| Selling, General & Admin | 49.08M | 2.24M | 1.76M | 42.92M | 15.39M |
| Operating Expenses | 168.7M | 14.01M | 13.46M | 55.26M | 46.14M |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| EBITDA | (169.84M) | (15.25M) | (14.01M) | (58.77M) | (41.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (169.82M) | (14.01M) | (13.46M) | (55.26M) | (46.15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.32M | 0 | 0 | 5.49M | 0 |
| Interest Expense | 0 | 235K | 687K | 0 | 1.44M |
| Other Income / Expenses | (1.14M) | (1.48M) | (1.24M) | (3.51M) | 2.71M |
| Income Before Tax | (170.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.01M | 0 | 0 | 0 | 0 |
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| EPS (Diluted) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| Weighted Avg Shares | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
| Weighted Avg Shares (Diluted) | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.